Skip to main content

A multi-center, randomized, double-blind, placebo controlled, parallel-group PhaseIIIb study evaluating the effect of inclisiran on atherosclerotic plaque progressionassessed by coronary computed tomography angiography (CCTA) in participantswith a diagnosis of non-obstructive coronary artery disease without previouscardiovascular events

Open
  • Protocol code: CKJX839D12303
  • EudraCT code: 2021-004601-47
  • Research group: Cardiovascular Diseases
  • Service: Cardiology
  • Principal investigator:  Rodríguez Palomares, Jose Fernando
  • Pathology: Malalties del sistema circulatori
  • Phase: Fase III
  • Status: Recruiting volunteers